目次

TABLE OF CONTENTS

1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 STUDY SCOPE
1.3.1 MARKETS COVERED & REGIONAL SCOPE
1.3.2 INCLUSIONS & EXCLUSIONS
1.3.3 YEARS CONSIDERED
1.3.4 CURRENCY CONSIDERED
1.4 STAKEHOLDERS
1.5 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.1.1 SECONDARY DATA
2.1.2 PRIMARY RESEARCH
2.2 MARKET SIZE ESTIMATION
2.2.1 GLOBAL MARKET ESTIMATION
2.2.1.1 Insights From Primary Experts
2.2.2 SEGMENTAL MARKET ESTIMATION (TOP-DOWN APPROACH)
2.3 MARKET GROWTH RATE PROJECTION
2.4 DATA TRIANGULATION
2.5 RESEARCH ASSUMPTIONS
2.6 RESEARCH LIMITATIONS
2.7 RISK ANALYSIS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS
4.1 CRISPR MARKET OVERVIEW
4.2 NORTH AMERICA: CRISPR MARKET, BY APPLICATION AND COUNTRY (2024)
4.3 CRISPR MARKET SHARE, BY END USER, 2025 VS. 2030

5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.1.1 Growing demand for CRISPR-based gene therapies
5.2.1.2 Advancements in CRISPR technology
5.2.1.3 Growing government and private investments and funding for CRISPR technology
5.2.2 RESTRAINTS
5.2.2.1 Technical challenges associated with CRISPR technology
5.2.3 OPPORTUNITIES
5.2.3.1 Development of new vaccines and treatments for genetic diseases
5.2.3.2 Expanding industrial and agricultural applications of CRISPR
5.2.4 CHALLENGES
5.2.4.1 Regulatory hurdles for CRISPR advancements
5.2.5 TECHNOLOGY ANALYSIS
5.2.5.1 Key technologies
5.2.5.1.1 CRISPR-Cas systems
5.2.5.1.2 gRNA design & optimization
5.2.5.1.3 High-throughput CRISPR screening
5.2.5.2 Complementary technologies
5.2.5.2.1 Synthetic biology
5.2.5.2.2 Single-cell genomics
5.2.5.2.3 Next-generation sequencing
5.2.5.3 Adjacent technologies
5.2.5.3.1 Stem cell engineering
5.2.5.3.2 Synthetic DNA & gene synthesis
5.2.5.3.3 Microfluidics
5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
5.4 SUPPLY CHAIN ANALYSIS
5.5 VALUE CHAIN ANALYSIS
5.6 ECOSYSTEM ANALYSIS
5.7 PORTER'S FIVE FORCES ANALYSIS
5.7.1 THREAT OF NEW ENTRANTS
5.7.2 THREAT OF SUBSTITUTES
5.7.3 BARGAINING POWER OF BUYERS
5.7.4 BARGAINING POWER OF SUPPLIERS
5.7.5 INTENSITY OF COMPETITIVE RIVALRY
5.8 REGULATORY ANALYSIS
5.8.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.8.2 REGULATORY FRAMEWORK
5.8.2.1 North America
5.8.2.1.1 US
5.8.2.1.2 Canada
5.8.2.2 Europe
5.8.2.2.1 Germany
5.8.2.2.2 UK
5.8.2.2.3 France
5.8.2.3 Asia Pacific
5.8.2.3.1 Japan
5.8.2.3.2 China
5.8.2.4 Latin America
5.8.2.4.1 Brazil
5.8.2.5 Middle East & Africa
5.8.2.5.1 GCC Countries
5.8.2.5.2 South Africa
5.9 PRICING ANALYSIS
5.9.1 AVERAGE SELLING PRICE OF KITS AND REAGENTS, BY KEY PLAYER (2024)
5.9.2 AVERAGE SELLING PRICE TREND OF CRISPR KITS & REAGENTS, BY KEY PLAYER, 2022-2024
5.9.3 INDICATIVE PRICE TREND FOR CRISPR SERVICES
5.9.4 AVERAGE SELLING PRICE TREND OF CRISPR KITS AND REAGENTS, BY REGION, 2024
5.10 PATENT ANALYSIS
5.11 KEY CONFERENCES & EVENTS, 2025-2026
5.12 KEY STAKEHOLDERS & BUYING CRITERIA
5.12.1 KEY STAKEHOLDERS IN BUYING PROCESS
5.12.2 CRISPR MARKET: BUYING CRITERIA
5.13 INVESTMENT & FUNDING SCENARIO
5.14 IMPACT OF AI ON CRISPR MARKET
5.15 TRADE ANALYSIS
5.15.1 IMPORT DATA FOR KITS & REAGENTS, 2019-2023
5.15.2 EXPORT DATA FOR KITS & REAGENTS, 2019-2023
5.15.3 TRUMP IMPACT OVERVIEW: CRISPR MARKET
5.15.3.1 Introduction
5.15.3.2 Key tariff rates
5.15.3.3 Price impact analysis
5.15.3.4 Key Impact on various regions
5.15.3.4.1 US
5.15.3.4.2 Europe
5.15.3.4.3 Asia Pacific
5.15.3.4.4 Rest of the World
5.15.3.5 End-use industry impact
5.15.3.5.1 Pharmaceutical & biotech companies
5.15.3.5.2 Contract research organizations (CROs)
5.15.3.5.3 Academic & research institutes

6 CRISPR MARKET, BY OFFERING
6.1 INTRODUCTION
6.2 PRODUCTS
6.2.1 ADVANCEMENTS IN GENOME EDITING TO DRIVE GROWTH
6.3 SERVICES
6.3.1 GROWING DEMAND FOR PRECISE GENOME EDITING TOOLS IN RESEARCH AND CLINICAL APPLICATIONS TO BOOST MARKET

7 CRISPR PRODUCTS MARKET, BY TYPE
7.1 INTRODUCTION
7.2 CRISPR KITS & ENZYMES
7.2.1 CRISPR KITS & ENZYMES SEGMENT TO DOMINATE CRISPR PRODUCTS MARKET DURING FORECAST PERIOD
7.3 CRISPR LIBRARIES
7.3.1 INCREASING APPLICATIONS OF CRISPR LIBRARIES IN GENE EDITING TO DRIVE GROWTH
7.4 OTHER PRODUCTS

8 CRISPR PRODUCTS MARKET, BY END USER
8.1 INTRODUCTION
8.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
8.2.1 INCREASING PRODUCT APPROVALS AND ROBUST CLINICAL PIPELINE TO PROPEL MARKET
8.3 ACADEMIC & RESEARCH INSTITUTES
8.3.1 INCREASING FUNDING FOR GENOMIC PROJECTS TO PROPEL MARKET
8.4 OTHER END USERS

9 CRISPR MARKET, BY SERVICE
9.1 INTRODUCTION
9.1.1 GRNA SYNTHESIS & CELL LINE DEVELOPMENT
9.1.1.1 Emerging opportunities in CRISPR gRNA synthesis & cell line development to drive growth
9.1.2 SCREENING & VALIDATION
9.1.2.1 Rapid advancements in CRISPR technology to drive growth
9.2 OTHER SERVICES

10 CRISPR SERVICES MARKET, BY END USER
10.1 INTRODUCTION
10.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
10.2.1 ADVANCEMENTS IN GENOME EDITING TO DRIVE GROWTH
10.3 ACADEMIC & RESEARCH INSTITUTES
10.3.1 INCREASING INVESTMENTS IN GENOMIC PROJECTS TO PROPEL MARKET
10.4 OTHER END USERS

11 CRISPR MARKET, BY APPLICATION
11.1 INTRODUCTION
11.2 DRUG DISCOVERY & DEVELOPMENT
11.2.1 ADVANCEMENTS IN GENOME EDITING TO DRIVE GROWTH
11.3 AGRICULTURE
11.3.1 GROWING DEMAND FOR ENHANCED CROP TRAITS TO DRIVE GROWTH
11.4 OTHER APPLICATIONS

12 CRISPR MARKET, BY REGION
12.1 INTRODUCTION
12.2 NORTH AMERICA
12.2.1 MACROECONOMIC OUTLOOK OF NORTH AMERICA
12.2.2 US
12.2.2.1 Increasing demand for CRISPR products and services across various industries to drive growth
12.2.3 CANADA
12.2.3.1 Increasing demand for gene-editing technologies to boost growth
12.3 EUROPE
12.3.1 MACROECONOMIC OUTLOOK OF EUROPE
12.3.2 GERMANY
12.3.2.1 Rapidly increasing biotechnology sector to support growth
12.3.3 UK
12.3.3.1 Significant government investments in genomics research to propel growth
12.3.4 FRANCE
12.3.4.1 Increasing demand for targeted therapies and personalized medicine to propel growth
12.3.5 ITALY
12.3.5.1 Increasing demand for innovative therapeutic solutions to drive growth
12.3.6 SPAIN
12.3.6.1 Increasing demand for precision medicine to drive growth
12.3.7 REST OF EUROPE
12.4 ASIA PACIFIC
12.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
12.4.2 CHINA
12.4.2.1 Increasing investments in R&D to drive growth
12.4.3 JAPAN
12.4.3.1 Potential of CRISPR-based therapies in personalized medicine to present opportunities for market growth
12.4.4 INDIA
12.4.4.1 Increasing prevalence of genetic disorders to support growth
12.4.5 REST OF ASIA PACIFIC
12.5 LATIN AMERICA
12.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
12.5.2 BRAZIL
12.5.2.1 Growing adoption of genome technologies to propel growth
12.5.3 REST OF LATIN AMERICA
12.6 MIDDLE EAST & AFRICA
12.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA

13 COMPETITIVE LANDSCAPE
13.1 INTRODUCTION
13.2 KEY PLAYER STRATEGY/RIGHT TO WIN
13.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN CRISPR MARKET
13.3 REVENUE ANALYSIS, 2020-2024
13.4 MARKET SHARE ANALYSIS, 2024
13.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
13.5.1 STARS
13.5.2 EMERGING LEADERS
13.5.3 PERVASIVE PLAYERS
13.5.4 PARTICIPANTS
13.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
13.5.5.1 Company footprint
13.5.5.2 Region footprint
13.5.5.3 Product footprint
13.5.5.4 Service footprint
13.5.5.5 Application footprint
13.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
13.6.1 PROGRESSIVE COMPANIES
13.6.2 RESPONSIVE COMPANIES
13.6.3 DYNAMIC COMPANIES
13.6.4 STARTING BLOCKS
13.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES
13.6.5.1 Detailed list of key startups/SMEs
13.6.5.2 Competitive benchmarking of key startups/SMEs
13.7 COMPETITIVE SCENARIO
13.7.1 PRODUCT LAUNCHES & APPROVALS
13.7.2 DEALS
13.7.3 EXPANSIONS
13.8 COMPANY VALUATION & FINANCIAL METRICS
13.9 BRAND/PRODUCT COMPARISON

14 COMPANY PROFILES
14.1 KEY PLAYERS
14.1.1 THERMO FISHER SCIENTIFIC INC.
14.1.1.1 Business overview
14.1.1.2 Products/Services offered
14.1.1.3 Recent developments
14.1.1.3.1 Product/Service launches
14.1.1.3.2 Deals
14.1.1.3.3 Expansions
14.1.1.4 MnM view
14.1.1.4.1 Key strengths
14.1.1.4.2 Strategic choices
14.1.1.4.3 Weaknesses & competitive threats
14.1.2 MERCK KGAA
14.1.2.1 Business overview
14.1.2.2 Products/Services offered
14.1.2.3 Recent developments
14.1.2.3.1 Deals
14.1.2.4 MnM view
14.1.2.4.1 Key strengths
14.1.2.4.2 Strategic choices
14.1.2.4.3 Weaknesses & competitive threats
14.1.3 AGILENT TECHNOLOGIES, INC.
14.1.3.1 Business overview
14.1.3.2 Products/Services offered
14.1.3.3 Recent developments
14.1.3.3.1 Deals
14.1.3.3.2 Expansions
14.1.3.4 MnM view
14.1.3.4.1 Key strengths
14.1.3.4.2 Strategic choices
14.1.3.4.3 Weaknesses & competitive threats
14.1.4 GENSCRIPT
14.1.4.1 Business overview
14.1.4.2 Products/Services offered
14.1.4.3 Recent developments
14.1.4.3.1 Product/service approvals/launches
14.1.4.3.2 Deals
14.1.4.3.3 Expansions
14.1.5 REVVITY
14.1.5.1 Business overview
14.1.5.2 Products/Services offered
14.1.5.3 Recent developments
14.1.5.3.1 Deals
14.1.6 LONZA
14.1.6.1 Business overview
14.1.6.2 Products/Services offered
14.1.6.3 Recent developments
14.1.6.3.1 Deals
14.1.7 DANAHER CORPORATION
14.1.7.1 Business overview
14.1.7.2 Products/Services offered
14.1.7.3 Recent developments
14.1.7.3.1 Deals
14.1.8 TAKARA BIO INC.
14.1.8.1 Business overview
14.1.8.2 Products/Services offered
14.1.8.3 Recent developments
14.1.8.3.1 Deals
14.1.9 CREATIVE BIOGENE
14.1.9.1 Business overview
14.1.9.2 Products/Services offered
14.1.9.3 Recent developments
14.1.9.3.1 Product/service approvals/launches
14.1.10 FUJIAN SUNYBIOTECH CO., LTD.
14.1.10.1 Business overview
14.1.10.2 Products/Services offered
14.1.11 EDITCO
14.1.11.1 Business overview
14.1.11.2 Products/Services offered
14.1.11.3 Recent financials
14.1.11.3.1 Deals
14.1.12 CARIBOU BIOSCIENCES, INC.
14.1.12.1 Business overview
14.1.12.2 Products/Services offered
14.1.12.3 Recent developments
14.1.12.3.1 Deals
14.1.13 HERA BIOLABS
14.1.13.1 Business overview
14.1.13.2 Products/Services offered
14.1.14 ORIGENE TECHNOLOGIES, INC.
14.1.14.1 Business overview
14.1.14.2 Products/Services offered
14.1.15 CELLECTA, INC.
14.1.15.1 Business overview
14.1.15.2 Products/Services offered
14.2 OTHER PLAYERS
14.2.1 MAMMOTH BIOSCIENCES, INC.
14.2.2 APPLIED STEMCELL
14.2.3 NEW ENGLAND BIOLABS
14.2.4 TOOLGEN, INC.
14.2.5 GENECOPOEIA, INC.
14.2.6 TWIST BIOSCIENCE
14.2.7 SYNTHEGO
14.2.8 EGENESIS
14.2.9 INSCRIPTA, INC.
14.2.10 PRECISION BIOSCIENCES

15 APPENDIX
15.1 DISCUSSION GUIDE
15.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
15.3 CUSTOMIZATION OPTIONS
15.4 RELATED REPORTS
15.5 AUTHOR DETAILS